SCHEMBL6798564

SCHEMBL6798564

CCOC(=O)c1cc2c(C(F)(F)F)cc(OS(=O)(=O)C(F)(F)F)cc2n1C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.36
ADORA1 P30542 1/20 0.36
KDM4E B2RXH2 4/20 0.36
ALOX5 P09917 2/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
MAOA P21397 1/20 0.34
NOD2 Q9HC29 1/20 0.33
NOD1 Q9Y239 1/20 0.33
ELANE P08246 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796884 0.84 AGER (0.40) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6797980 0.83 POLB (0.38) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6799070 0.82 POLB (0.41) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6799072 0.82 GAA (0.41) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6795763 0.82 POLB (0.38) KDM4EALOX5ALDH1A1HPGDL3MBTL1
SCHEMBL6797977 0.81 ALOX5 (0.44) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL7881981 0.81 SRD5A2 (0.45) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6797518 0.80 KDM4E (0.40) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6798912 0.80 KDM4E (0.37) LDHAKDM4EALOX5ALDH1A1CYP1A2
SCHEMBL6798023 0.79 ALDH1A1 (0.39) LDHAKDM4EALOX5ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 LDHA 2166/4885ADORA1 233/4885KDM4E 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.